Drugs of the future: the hormone relaxin

被引：80

作者：

Samuel, C. S. ^{[1
]}

Hewitson, T. D.

Unemori, E. N.

Tang, M. L. -K.

机构：

[1] Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia

[2] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia

[3] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia

[4] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic 3050, Australia

[5] BAS Med, San Mateo, CA 94402 USA

[6] Royal Childrens Hosp, Dept Allergy, Parkville, Vic 3052, Australia

[7] Royal Childrens Hosp, Dept Immunol, Parkville, Vic 3052, Australia

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2007年 / 64卷 / 12期

关键词：

relaxin; RXFP1; therapeutic; fibrosis; inflammation; cardioprotection; vasodilation; wound healing;

D O I：

10.1007/s00018-007-6543-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The peptide hormone relaxin is emerging as a multi-functional factor in a broad range of target tissues including several non-reproductive organs, in addition to its historical role as a hormone of pregnancy. This review discusses the evidence that collectively demonstrates the many diverse and vital roles of relaxin: the homeostatic role of endogenous relaxin in mammalian pregnancy and ageing; its gender-related effects; the therapeutic effects of relaxin in the treatment of fibrosis, inflammation, cardioprotection, vasodilation and wound healing (angiogenesis) amongst other pathophysiological conditions, and its potential mechanism of action. Furthermore, translational issues using experimental models (to humans) and its use in various clinical trials, are described, each with important lessons for the design of future trials involving relaxin. The diverse physiological and pathological roles for relaxin have led to the search for its significance in humans and highlight its potential as a drug of the future.

引用

页码：1539 / 1557

页数：19

共 148 条

[1] Relaxin activates the L-arginine nitric oxide pathway in vascular smooth muscle cells in culture [J].

Bani, D ;

Failli, P ;

Bello, MG ;

Thiemermann, C ;

Sacchi, TB ;

Bigazzi, M ;

Masini, E .

HYPERTENSION, 1998, 31 (06) :1240-1247

[2] Relaxin: A pleiotropic hormone [J].

Bani, D .

GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 28 (01) :13-22

[3] Basic progress and future therapeutic perspectives of relaxin in ischemic heart disease [J].

Bani, D ;

Nistri, S ;

Sacchi, TB ;

Bigazzi, M .

RELAXIN AND RELATED PEPTIDES: FOURTH INTERNATIONAL CONFERENCE, 2005, 1041 :423-430

[4] Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs [J].

Bani, D ;

Ballati, L ;

Masini, E ;

Bigazzi, M ;

Sacchi, TB .

ENDOCRINOLOGY, 1997, 138 (05) :1909-1915

[5]

Bani D, 1998, AM J PATHOL, V152, P1367

[6] RELAXIN-INDUCED INCREASED CORONARY FLOW-THROUGH STIMULATION OF NITRIC-OXIDE PRODUCTION [J].

BANISACCHI, T ;

BIGAZZI, M ;

BANI, D ;

MANNAIONI, PF ;

MASINI, E .

BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (01) :1589-1594

[7] International union of pharmacology LVII: Recommendations for the nomenclature of receptors for relaxin family peptides [J].

Bathgate, RA ;

Ivell, R ;

Sanborn, BM ;

Sherwood, OD ;

Summers, RJ .

PHARMACOLOGICAL REVIEWS, 2006, 58 (01) :7-31

[8] Relaxin-3:: Improved synthesis strategy and demonstration of its high-affinity interaction with the relaxin receptor LGR7 both in vitro and in vivo [J].

Bathgate, RAD ;

Lin, F ;

Hanson, NF ;

Otvos, L ;

Guidolin, A ;

Giannakis, C ;

Bastiras, S ;

Layfield, SL ;

Ferraro, T ;

Ma, S ;

Zhao, CX ;

Gundlach, AL ;

Samuel, CS ;

Tregear, GW ;

Wade, JD .

BIOCHEMISTRY, 2006, 45 (03) :1043-1053

[9]

BATHGATE RAD, 2006, PHYSL REPROD, P679

[10] The role of tubulointerstitial injury in chronic renal failure [J].

Becker, GJ ;

Hewitson, TD .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2000, 9 (02) :133-138

← 1 2 3 4 5 6 7 8 9 10 →